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Abstract
Background—In pregnancy associated malaria (PAM), Plasmodium falciparum infected
erythrocytes (IEs) express variant surface antigens (VSA-PAM) that evade existing immunity and
mediate placental sequestration. Antibodies to VSA-PAM develop with gravidity and block placental
adhesion or opsonise IEs for phagocytic clearance, protecting women from anemia and low birth
weight
Methods and findings—Using sera from 141 parasitemic pregnant Malawian women enrolled
in a randomized trial of antimalarials and VSA-PAM-expressing CS2 IEs, we quantitated levels of
IgG to VSA-PAM by flow cytometry and opsonizing antibodies by measuring uptake of IEs by THP1
promonocytes. After controlling for gravidity and antimalarial treatment, IgG against VSA-PAM
was associated with decreased anemia at delivery (OR=0.66, 95% confidence interval [CI] 0.46,
0.93; P=0.018) and weakly associated with decreased parasitological failure (OR=0.78; 95% CI,
0.60, 1.03; P=0.075), especially re-infection (OR=0.73; CI, 0.53,1.01; P=0.057). Opsonizing
antibodies to CS2 IE were associated with less maternal anemia. (OR=0.31, 95% CI, 0.13, 0.74;
P=0.008) and treatment failure (OR=0.48; 95% CI, 0.25, 0.90; P=0.023), primarily due to
recrudescent infection (OR=0.49; 95% CI, 0.21, 1.12; P=0.089).
Conclusion—Both IgG antibody to VSA-PAM and opsonizing antibody, a functional measure of
immunity correlate with parasite clearance and less anemia in pregnancy malaria.
INTRODUCTION
Globally, 247 million people are infected with malaria every year[1], which causes 881,000
deaths annually. Pregnant women have an increased risk of Plasmodium falciparum infection
which is maximal in the first and second pregnancy [2]. Maternal malaria infection occurs
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partly because infected erythrocytes (IEs) accumulate in the placenta [3]. Studies suggest that
the var2csa variant of P. falciparum membrane protein 1 (PfEMP1) is the key protein which
mediates this accumulation [4].
Women acquire immunity to pregnancy associated malaria (PAM) by generating antibodies
against PAM variant surface antigens (VSA-PAM) in a gravidity dependent manner [5–8]. The
level of PAM-specific antibodies remains low before their first or even second pregnancy and
increases significantly with increased gravidity. These antibodies have been associated with
protection from maternal malaria and its consequences in subgroups of pregnant women [5,
9,10]. This protection may result from blocking binding of IEs to chondroitin sulfate A (CSA)
on syncytiotrophoblasts in the placenta [5,8,11], or from promoting clearance by opsonic
phagocytosis of IE in the peripheral blood and the placenta [12–14]. Levels of opsonizing
antibodies are correlated with levels of PAM specific IgG [12], but their relationship to clinical
outcomes is unknown.
Host immunity against malaria is believed to be an important factor in malaria treatment success
[15], and studies in children or non-immune adults have demonstrated associations between
specific measures of immunity to malaria, most commonly levels or titres of IgG to defined
antigens measured by ELISA, and treatment outcome [16–21]. Such studies are lacking in
pregnant women.
Prevention of malaria in pregnancy in Africa still relies on sulphadoxine-pyrimethamine (SP),
but parasite resistance leads to treatment failures in children [22]. Beneficial effects of SP are
seen in pregnant women, even where there are moderate levels of pediatric treatment failure
[23]. We hypothesized that immunity to VSA-PAM, and in particular levels of antibodies that
opsonise IE for phagocytic clearance, could be important components of the acquired maternal
immune response involved in clearing infection and protecting pregnant women from treatment
failure and adverse pregnancy outcomes.
In the present study we compared a recently developed assay for VSA-PAM specific opsonic
activity with flow cytometry measurements of total IgG to VSA-PAM to measure antibody in
sera collected from parasitemic Malawian women in mid pregnancy. Antibody levels with each
assay were examined as predictors of clinical outcomes including treatment success, maternal
anemia at delivery and birth weight.
METHODS
Study population
141 serum samples were collected during a randomized clinical trial of antimalarials for
treatment of parasitemia in pregnancy, conducted at Mpemba and Madziabango Health Centers
in Blantyre District, Malawi from September, 2003 to September, 2004 [24]. Women 14–26
weeks pregnant, with parasitemia on peripheral blood film, were eligible to participate whether
or not they had symptoms. Participants were randomly assigned to SP (3 tablets; 500 mg
sulfadoxine and 25 mg pyrimethamine per tablet); SP plus azithromycin (1 g/day for 2 days)
or SP plus artesunate (200 mg/day for 3 days) treatment groups. All participants received 2
doses of drug treatment irrespective of whether or not they experienced recurrence of
parasitemia. Participants’ general demographic information and malaria infection history were
collected together with blood samples at time of enrolment. All the participants were followed
up until delivery. At delivery, infant birth weight and mothers’ and infants’ hemoglobin
concentrations were recorded. Anemia was defined as maternal hemoglobin lower than 11 g/
dl and low birth weight was defined as infant’s birth weight lower than 2500 g. Parasitological
treatment failure was defined as a further episode of parasitemia from the 7th day after treatment
till the end of study, and Heteroduplex Tracking Assays were performed to distinguish
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recrudescence (isolation of genetically identical parasites at a subsequent time point) from re-
infection (isolation of novel parasite types not seen on enrolment), based on polymorphisms
in the merozoite surface protein 1 (msp-1) gene [25].
Culture of Plasmodium falciparum
The laboratory adapted P. falciparum line CS2 which expresses var2csa and binds to CSA was
cultured in RPMI-HEPES with 0.5% Albumax and 0.18% NaHCO3. A second P. falciparum
line, E8B-ICAM, which binds to ICAM-1 was cultured in RPMI-HEPES with 0.25% Albumax,
5% heat-inactivated human serum and 0.18% NaHCO3. All parasites were synchronized by
gelatin selection weekly [26].
Culture of THP1 cells
THP1 cells were maintained in RPMI-1640 with 0.002 mol/L L-glutamine 1.5 g/L sodium
bicarbonate, 0.01 mol/L HEPES, 5×10−5 mol/L 2-mercaptoethanol, and 10% fetal bovine
serum. Cell density was monitored closely between 1×105 and 1×106 cell/ml. Cells were
passaged every 6 days, when cell density approached 1×106 cells/ml.
Flow cytometry
In vitro cultured IEs were used at 4% to 8% parasitemia to quantify total level of IgG against
VSA expressed on the surface of erythrocytes infected with CS2 or E8B-ICAM parasite lines.
After washing with 0.1% newborn calf serum (NCS) in phosphate buffered saline (PBS), IEs
were resuspended at 0.1% haematocrit in 0.1% NCS in PBS and incubated with individual
serum samples at 1:20 (v/v) for 30 minutes. Then IEs were washed three times with 0.1% NCS
in PBS and incubated with Polyclonal Rabbit Anti-Human IgG (Dako A0424) at 1:100 dilution
for 30 minutes, followed by three washes and incubation with Alexa Fluor 488 donkey anti-
rabbit IgG (Molecular Probes A-21206) at 1:500 dilution plus 10 μg/ml ethidium bromide
(EtBr) for 30 minutes. Using a FACScalibur with CELLQuest software, two thousand IEs were
counted, and geometric mean of fluorescence intensity was recorded. Pooled sera from
Malawian hyperimmune multigravid women were used as a positive control, while the negative
control was pooled sera from malaria-naive Melbourne donors. Both positive and negative
controls were included in each assay. Adjusted mean fluorescence intensity (MFI) was
calculated by subtracting the MFI in channel FL1 of the EtBr negative cell population from
that of the EtBr positive cell population. Finally we used the relative level of IgG compared to
the positive control (relative MFI) as the indicator of total IgG level.
Opsonic phagocytosis
We adapted previously published methods to examine phagocytic uptake of opsonised IEs
[13,27]. THP1 cells were plated into 96-well plates at 5×104 cells/well in THP1 culture medium
plus 1×10−7 mol/L phorbol myristate acetate (PMA) for 12–24 hours to allow differentiation
to adherent macrophage-like cells. This was replaced with culture medium without PMA on
the second day and cells were incubated for a further 2–3 days before use.
Trophozoite-stage CS2 IEs at ≥ 8% parasitemia were purified by percoll gradient centrifugation
to 90–95% parasitemia, followed by 3 washes in fetal calf serum (FCS) coated tubes and
resuspended in cold PBS. 2.25 μl of heat-inactivated patient sera were incubated with 8 ×
106 IEs for 1 hour at room temperature for opsonization. Unbound serum components were
removed by 3 washes with PBS and 1×106 IEs were added to wells containing THP1 cells in
quadruplicate and incubated for 2 hours to allow phagocytosis. After incubation, 100 μl cold
PBS was added to each well to stop phagocytosis, followed by incubation for 3 min in 100 μl
0.2% NaCl to lyse non-phagocytosed IEs. The wells were washed 4 times with warm THP1
culture media to remove lysed IEs. THP1 cells and phagocytosed IEs were lysed by adding
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100 μl 0.2 mol/L Tris-HCl, 6 mol/L urea for 30 minutes to release hemoglobin. After lysing
the cells, 100μl 1 mg/ml 2,7-diaminofluorene (Sigma D17106–1G) with 0.3% hydrogen
peroxide was added into each well, and hemoglobin release was measured
spectrophotometrically at 620 nm. Standard curves were constructed in triplicate using
unopsonized IEs from the same culture. Eleven 2-fold serial dilutions were made from a starting
concentration of 2.5 × 105 unopsonized cells. The standard curve was used to estimate the
number of ingested erythrocytes from the amount of hemoglobin released which was then
converted to a phagocytic index of ingested erythrocytes per 100 macrophages. The same
pooled serum from multigravid Malawian pregnant women described above was used as a
positive control. Relative Phagocytosis Index (relative PI) was calculated for each individual
serum sample as the percentage of phagocytic index obtained using the positive control pooled
serum.
Statistical analysis
Data were entered into Microsoft EXCEL and analyzed using Stata 9.2 (StataCorp, College
Station, Texas, USA). Total level of IgG (relative MFI) and total level of opsonic antibodies
(relative PI) were log to the base 2 transformed. The associations between relative MFI or
relative PI and gravidity were estimated using linear regression. To investigate the association
between immunity against PAM and malaria treatment outcome, maternal anemia and infants’
birth weight, relative MFI against CS2 and E8B-ICAM and relative PI at enrollment were
defined as exposure variables. Recrudescence, re-infection, parasitological failure, maternal
anemia at delivery and infant low birth weight were defined as outcome variables. Maternal
gravidity which was classified as first pregnancy and second or subsequent pregnancies was
considered as a confounding factor, as was participant’s treatment group. Multiple logistic
regression was performed to investigate the association between exposure and outcomes
variables with adjustment for gravidity and treatment group.
Ethics
Ethics approval was obtained from the College of Medicine Research Ethics Committee,
University of Malawi and from the Melbourne Health Human Research Ethics Committee.
RESULTS
Summary of study population
Serum samples were tested from 141 pregnant women with a mean age of 21.2 years (SD =
4.7). Characteristics of the study population are listed in Table 1. 47 participants were assigned
to SP mono-therapy group; 47 participants were assigned to the SP plus azithromycin group;
47 participants were assigned to the SP plus artesunate group.
Relative MFI against CS2 IE increased with gravidity. Linear regression showed that the
relative MFI against CS2 IEs was higher in secundigravidae (ratio of geometric means=2.01;
95% CI: 1.17, 3.43 P=0.012) and multigravidae (ratio of geometric means =2.62; 95% CI: 1.82,
3.78; P<0.001) compared with primigravidae. In contrast, the relative MFI against E8B-ICAM
did not differ between the gravidity groups (Figure 1A, 1B).
Relative PI was similar between primigravid and secundigravid women (ratio of geometric
means = 1.05; 95% CI: 0.84, 1.32; P=0.680), however, it was significantly higher in multigravid
women compared to primigravid women (ratio of geometric means = 1.64; 95% CI: 1.39, 1.91;
P<0.001) (Figure 1C). There was a moderate correlation between relative PI and total IgG
against CS2 IEs (R = 0.56, P<0.001).
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Immunity against PAM: Association with malaria treatment outcome
Both relative MFI against CS2 IEs and relative PI were associated with measures of treatment
outcome. The associations between relative MFI against CS2 IEs or relative PI and
parasitological failure are shown in Table 2, Table 3 and Figure 2. Every two fold increase in
relative MFI against CS2 IEs, which is the indicator of total level of IgG against VSA-PAM,
was associated with a 22% reduction in the odds of parasitological failure after malaria
treatment (OR=0.78; 95% CI: 0.60, 1.03; P=0.075). A similar, but stronger association was
observed between relative PI and parasitological failure (OR=0.48; 95% CI: 0.25, 0.90,
P=0.023).
When parasitological failures were classified as recrudescence or re-infections [25], relative
MFI against CS2 IEs was associated with both recrudescence and re-infection at a marginally
significant level (Table 2). Every two fold increase in relative MFI against CS2 IEs was
associated with a 25% decrease in the odds of recrudescence (OR=0.75; 95% CI: 0.56, 1.01;
P=0.057) and a 23% decrease in the odds of re-infection (OR=0.77; 95% CI: 0.57, 1.03;
P=0.083). After adjustment for gravidity and treatment group, the relationship with
recrudescence was no longer significant, but there remained a marginally significant
relationship with risk of re-infection (OR=0.73, 95% CI: 0.53, 1.01; p=0.057). Relative PI was
more strongly associated with the risk of recrudescence (Table 3). For each 2 fold increase in
relative PI there was a 59% decrease in the odds of recrudescence (OR=0.41; 95% CI, 0.20,
0.85; P=0.016). After adjustment for gravidity and treatment, the magnitude of the effect
attenuated slightly (OR=0.49, 95% CI: 0.21, 1.12, p=0.089).
Immunity against PAM: Association with maternal anemia and infants’ low birth weight
Host immunity against PAM was associated with risk of maternal anemia at delivery. Both
relative MFI against CS2 IEs and relative PI were significantly associated with a decrease in
the risk of maternal anemia. As shown in table 2 and figure 3, a 2 fold increase in relative MFI
against CS2 IEs was associated with 36% decrease in the odds of maternal anemia (OR=0.64;
95% CI: 0.46, 0.88; P=0.007). Relative PI was more strongly associated with a decreased odds
of anemia (figure 3). Logistic regression showed that a 2 fold increase in relative PI was
associated with 70% reduction in the odds of maternal anemia (OR=0.30; 95% CI: 0.13, 0.68;
P=0.004). These associations remained highly significant after adjusting for gravidity and
treatment group (table 3).
Levels of IgG to E8B-ICAM were not associated with parasitological failure (OR=0.99 95%:
CI 0.75, 1.30; P=0.935) or maternal anemia (OR=0.94; 95% CI 0.67, 1.32; P=0.714). Relative
MFI and relative PI against CS2 IEs and relative MFI against E8B-ICAM IEs were not
associated with infant birth weight, or the risk of low birth weight (<2500 g) delivery.
DISCUSSION
We measured levels of total IgG to VSA-PAM (relative MFI against CS2 IEs) and opsonic
antibodies against VSA-PAM (relative PI) in sera from parasitemic pregnant women, and
related antibody measures to treatment and pregnancy outcomes. As in previous studies, we
found that antibody-mediated immunity against VSA-PAM was generated in a gravidity
dependent manner [5,7,8,12,28,29], whereas antibody to VSA of the parasite line E8B-ICAM
was not.
Both opsonizing antibodies and total IgG to VSA-PAM were associated with treatment
outcome and with a lower prevalence of maternal anemia at delivery, but the relationship
between opsonizing antibody levels and treatment outcome or maternal anemia was stronger
than that between total IgG to VSA-PAM and outcome, suggesting that measurement of the
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opsonizing function of antibodies may be a more specific assay of the protective effect of IgG
in patient sera. These data provide the first evidence that antibodies against VSA-PAM
expressed on the surface of CSA-binding IEs may be important determinants of malaria
treatment outcome in pregnant women; moreover, they may be useful predictors of anemia as
a consequence of such infection.
Outcome of malaria treatment varies with age [15], and relatively more pregnant women than
children clear infection when treated with a partially effective drug [30]. Primigravid women,
who are at highest risk of malaria in pregnancy, are more likely to fail drug treatment than
multigravidae [31]. Our data suggest that this may be attributable, at least in part, to the lower
levels of antibody to VSA-PAM found in primigravidae [8,12].
Antibodies of the cytophilic subclasses IgG1 and IgG3 can opsonise infectious agents for
phagocytosis, and IgG1 and IgG3 responses to VSA-PAM develop in a gender and parity
dependent manner [28,29]. The Fc domains of cytophilic antibodies bind to Fc receptors
expressed on the surface of macrophages followed by phagocytic clearance. Decreased
antibody to VSA-PAM may partly explain susceptibility of HIV infected pregnant women to
malaria[32], and Keen et al recently reported that HIV infection significantly decreases opsonic
activity and levels of IgG1 and IgG3 directed against VSA-PAM in pregnant Kenyan women.
[12] Together with our observations that opsonizing antibodies are important predictors of
treatment outcome and are associated with protection from anemia, this suggests that opsonic
activity is a biologically important function of PAM-specific antibodies in addition to their
ability to prevent placental sequestration.
Antibodies against maternal malaria could block IEs adhering to CSA preventing placental
sequestration [5,9,10], or they may opsonise IEs and promote phagocytic clearance [12,13].
We chose not to test sera for adhesion-blocking antibodies in this study, because in a separate
cohort we found weaker correlations between assays of these antibodies and either HIV
serostatus or pregnancy outcomes [33]. It would nevertheless be of interest to compare different
assays, including assays directly measuring antibody to VAR2CSA protein, the dominant
VSA-PAM (reviewed in [6,34]), in longitudinal studies such as this.
The optimal format for assays of opsonizing activity has yet to be resolved. Keen et al assayed
opsonizing antibody using thioglycollate elicited mouse macrophages or human monocyte
derived macrophages and direct counting of ingested cells by microscopy [12]. We used PMA-
primed THP1 human promonocytic cells and adapted a published protocol [13] to give a
spectrophotometric measure of ingested erythrocytes using a 96 well plate format [27,35],
allowing increased throughput, necessary for clinical studies. Primary human macrophages are
most relevant to the in vivo situation, but inter-host variability in phagocytic activity [36] makes
them less useful for large sample sets, because of the need to use cells from multiple donors.
We are examining protocol modifications that might allow sample sets of 100–200 sera to be
tested using the same cells. In each case, it is unlikely that other host serum factors influence
assay outcome, as opsonization is followed by extensive washing before opsonized IEs are
added to macrophages.
Malaria in pregnancy may cause anemia, which is a risk factor for maternal mortality and
morbidity, as well as for low birth weight of the offspring [37]. In Malawi, the risk of anemia
at delivery among malaria infected pregnant women decreases with increased gravidity [38].
Maternal anemia is caused by a variety of factors [6,34] but, as our data show, opsonizing
antibody at time of study entry was associated with significantly lower risk of anemia at
delivery. Every 10 units increase in relative PI against CS2 IEs resulted in approximately 50%
decrease in the prevalence of anemia at delivery. A similar, but weaker, relationship was seen
between relative MFI against CS2 IEs and anemia. We previously demonstrated a strong
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epidemiological association between malaria and mild or moderate degrees of anemia in
pregnancy in Malawi [38]. Opsonizing antibodies may facilitate clearance of malaria infection,
and remove its effects on red cell destruction and suppression of erythropoiesis [39].
Our data suggest that opsonizing antibodies may also protect pregnant women from recurrence
of parasitemia after intermittent preventive treatment, which is recommended by WHO as an
important prevention approach against PAM. Moreover, this increased immunity decreases the
risk of maternal anemia. Our sample size precluded us from restricting analysis to women of
a specific gravidity, as others have done [5,9,10], and we did not find any relationship between
either antibody measure and birth weight.
Because our study had a relatively small sample size we could not investigate if the associations
between antibody response and the outcome measures were modified by gravidity or treatment.
The levels of antibodies to VSA-PAM (and especially of opsonizing antibodies) remained
significantly associated with treatment outcome and protection from anemia after controlling
for these variables except for relative MFI in association with parasitological failure (Tables
2 and 3). When treatment failures were divided into recrudescences and re-infections, total IgG
to VSA-PAM was particularly associated with a decrease in new infections, whereas
opsonizing antibody was associated with protection from recrudescence, although this was of
borderline significance (OR 0.49, CI 0.21–1.12, p=0.089). Further studies are required to
confirm these findings, which suggest that opsonizing antibodies may play a particularly
important role in elimination of infection in pregnant women.
HIV is known as an important factor in malaria infection [40,41], however, only 78 (55%)
participants were tested for HIV infection. Among this subgroup, HIV infection was not
correlate with either measurement of immunity against PAM (data not shown). Thus we did
not adjust our results for HIV infection.
In conclusion, opsonic phagocytosis was particularly strongly associated with decreased risk
of further episodes of parasitemia, or of maternal anemia at delivery, suggesting that opsonizing
antibodies form a key component of immunity to malaria in pregnant women. These potential
protective effects suggest that active immunization with vaccines against VSA-PAM that elicit
opsonizing antibodies may improve effectiveness of preventive treatment and pregnancy
outcomes. Development of simple assays of antibody to VSA-PAM may allow identification
of women who are at particular risk of complications of pregnancy malaria.
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Relationship between antibody to VSA and gravidity. Dot plot show individual values and line
indicate the median of relative MFI in each group. (A) Total level of IgG (relative MFI) against
CS2 IEs at enrollment in each gravidity group. (B) Total level of IgG (relative MFI) against
E8B-ICAM IEs at enrollment in each gravidity group. (C) Level of opsonic antibodies (relative
PI) in each gravidity group.
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Level of opsonic antibodies (relative PI) and total level of IgG (relative MFI) against CS2 IEs
in patients with parasitological failure vs. patients who cleared infection and remained parasite
free (Parasitological response). Dot plots show individual values; line indicates the median of
relative MFI and relative PI in each group.
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Level of opsonic antibodies (relative PI) and total level of IgG (relative MFI) against CS2 IEs
in patients with anemia vs. patients without anemia at delivery. Dot plots show individual
values; line indicates the median of relative MFI and relative PI in each group.
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